BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys") and SpayVac for Wildlife, Inc. are pleased to ...
The new machinery, called a "chimeric antigen receptor" or "Car," transforms a diverse T-cell population into Car-T, where the engineered cells all respond to the same cancer-associated marker. Both ...
The phase 2 CELLVX-230 trial is assessing the potential of FK-PC101 to prevent prostate cancer recurrence and delay ...
Press Release4BIO Capital Portfolio Company Trogenix Unveils Revolutionary Platform to Transform Cancer Treatment Through Precision Viral ...
Radiation therapy (RT) is a cornerstone in cancer treatment, known for its ability to induce tumor cell death and modulate ...
T cell-based immunotherapies including immune checkpoint blockade and chimeric antigen receptor T cells can induce durable responses in patients with cancer. However, clinical efficacy is limited due ...
A new phase 1 trial demonstrates the safety and effectiveness of personalized neoantigen DNA vaccines, showing promising ...
A novel test developed by Duke-NUS researchers enables real-time monitoring of T cells that have been engineered to fight cancer, after re-introduction into the body of a cancer patient.
GlobalData on MSN4d
AC Immune’s stock jumps after Parkinson’s therapy shows signs of benefitAC Immune’s Phase II trial showed an increase in anti-a-syn antibodies following treatment with the Parkinson’s disease ...
Immunotherapy, which enhances the immune system's T cell response to eliminate cancer cells, has emerged as a key approach in ...
A novel test developed by Duke-NUS researchers enables real-time monitoring of T cells that have been engineered to fight ...
Trials with mice in whom the researchers implanted human glioblastoma cells have already shown that the treatment is very ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback